Ken Griffin Bluebird Bio, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 164,400 shares of BLUE stock, worth $57,539. This represents 0.0% of its overall portfolio holdings.

Number of Shares

164,400

Previous 195,800 16.04%

Holding current value

$57,539

Previous $191,000 55.5%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $967 - $1,433	-1,138 Reduced 0.54%	207,802 $203,000
Q1 2024 May 15, 2024	SELL	$0.91 - $1.75 $1.16 Million - $2.23 Million	-1,274,890 Reduced 85.92%	208,940 $267,000
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $925,920 - $3.39 Million	701,455 Added 89.66%	1,483,830 $2.05 Million
Q3 2023 Nov 14, 2023	BUY	$3.02 - $4.05 $1.04 Million - $1.39 Million	343,341 Added 78.2%	782,375 $2.38 Million
Q2 2023 Aug 14, 2023	SELL	$2.79 - $5.03 $4.86 Million - $8.76 Million	-1,742,336 Reduced 79.87%	439,034 $1.44 Million
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $6.09 Million - $15.9 Million	1,938,566 Added 798.41%	2,181,370 $6.94 Million
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $4.02 Million - $5.92 Million	-697,143 Reduced 74.17%	242,804 $1.68 Million
Q3 2022 Nov 14, 2022	SELL	$3.75 - $7.39 $211,631 - $417,054	-56,435 Reduced 5.66%	939,947 $5.95 Million
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $2.45 Million - $4.36 Million	834,257 Added 514.58%	996,382 $4.13 Million
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $594,993 - $1.55 Million	146,190 Added 917.41%	162,125 $786,000
Q4 2021 Feb 14, 2022	SELL	$8.96 - $16.31 $73,274 - $133,383	-8,178 Reduced 33.92%	15,935 $159,000
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $655,674 - $1.23 Million	-58,334 Reduced 70.75%	24,113 $461,000
Q2 2021 Aug 16, 2021	BUY	$18.04 - $22.09 $733,452 - $898,113	40,657 Added 97.29%	82,447 $1.71 Million
Q1 2021 May 17, 2021	SELL	$16.59 - $33.89 $528,291 - $1.08 Million	-31,844 Reduced 43.25%	41,790 $1.26 Million
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $5.53 Million - $7.63 Million	-201,112 Reduced 73.2%	73,634 $3.19 Million
Q3 2020 Nov 16, 2020	BUY	$34.44 - $43.75 $5.66 Million - $7.2 Million	164,469 Added 149.14%	274,746 $14.8 Million
Q2 2020 Aug 14, 2020	SELL	$27.12 - $45.97 $25.9 Million - $43.9 Million	-955,874 Reduced 89.66%	110,277 $6.73 Million
Q1 2020 May 15, 2020	BUY	$26.16 - $63.5 $7.14 Million - $17.3 Million	272,897 Added 34.4%	1,066,151 $49 Million
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $27 Million - $35.5 Million	575,745 Added 264.7%	793,254 $69.6 Million
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $11.4 Million - $17.9 Million	191,833 Added 747.13%	217,509 $12.9 Million
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $1.59 Million - $2.2 Million	20,945 Added 442.72%	25,676 $3.27 Million
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $673,269 - $1.09 Million	-10,448 Reduced 68.83%	4,731 $0
Q3 2018 Nov 13, 2018	SELL	$88.86 - $117.49 $12.9 Million - $17 Million	-144,788 Reduced 90.51%	15,179 $0
Q2 2018 Aug 10, 2018	BUY	$99.64 - $127.59 $11.7 Million - $15 Million	117,185 Added 273.91%	159,967 $0
Q1 2018 May 11, 2018	SELL	$105.8 - $150.94 $4.28 Million - $6.11 Million	-40,452 Reduced 48.6%	42,782 $7.31 Million
Q4 2017 Feb 09, 2018	BUY	$81.25 - $130.7 $6.32 Million - $10.2 Million	77,726 Added 1411.15%	83,234 $14.8 Million
Q3 2017 Nov 09, 2017	BUY	$57.74 - $91.42 $318,031 - $503,541	5,508	5,508 $757,000

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account